Brexpiprazole as an augmentation agent to antidepressants in treatment resistant major depressive disorder

References

• Sheehan DV, Nakagome K, Asami Y, et al. Restoring function in major depressive disorder: A systematic review. J Affect Disord. 2017;215:299–313.
   PubMed Web of Science ®Google Scholar
• Beyer JL, Weisler RH. Adjunctive brexpiprazole for the treatment of major depressive disorder. Expert Opin Pharmacother. 2016;17:2331–2339.
   PubMed Web of Science ®Google Scholar
• Weisler RH, Ota A, Tsuneyoshi K, et al. Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment. J Affect Disord. 2016;204:40–47.
   PubMed Web of Science ®Google Scholar
• Mokdad AH, Mensah GA, Krish V, et al. Global, regional, national, and subnational big data to inform health equity research: perspectives from the global burden of disease study 2017. Ethn Dis. 2019;29:159–172.
   PubMed Web of Science ®Google Scholar
• Collins PY, Patel V, Joestl SS, et al. Grand challenges in global mental health. Nature. 2011;475:27–30.
   PubMed Web of Science ®Google Scholar
• Greenberg PE, Fournier -A-A, Sisitsky T, et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76:155–162.
   PubMed Web of Science ®Google Scholar
• Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: How did it change between 1990 and 2000? J Clin Psychiatry. 2003;64:1465–1475.
   PubMed Web of Science ®Google Scholar
• Wallace E, Salisbury C, Guthrie B, et al. Managing patients with multimorbidity in primary care. BMJ. 2015;350:h176.
   PubMed Web of Science ®Google Scholar
• Chisholm D, Sweeny K, Sheehan P, et al. Scaling-up treatment of depression and anxiety: a global return on investment analysis. Lancet Psychiatry. 2016;3:415–424.
   PubMed Web of Science ®Google Scholar
• Sussman M, Yu J, Kamat SA, et al. Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder. J Affect Disord. 2017;207:54–62.
   PubMed Web of Science ®Google Scholar
• Thase ME. Adverse effects of second-generation antipsychotics as adjuncts to antidepressants: are the risks worth the benefits? Psychiatr Clin North Am. 2016;39:477–486.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Filteau M-J, Martin L, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. 2014;156:1–7.
   PubMed Web of Science ®Google Scholar
• Knoth RL, Bolge SC, Kim E, et al. Effect of inadequate response to treatment in patients with depression. Am J Manag Care. 2010;16:e188–96.
   PubMed Web of Science ®Google Scholar
• Rush AJ, John Rush A, Trivedi MH, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–1917.
   PubMed Web of Science ®Google Scholar
• Brexpiprazole. Drugs and lactation database (LactMed). Bethesda (MD): National Library of Medicine (US); 2018.
   Google Scholar
• Ma M, Ren Q, Yang C, et al. Adjunctive treatment of brexpiprazole with fluoxetine shows a rapid antidepressant effect in social defeat stress model: Role of BDNF-TrkB signaling. Sci Rep. 2016;6:39209.
   PubMed Web of Science ®Google Scholar
• Ma M, Ren Q, Fujita Y, et al. Alterations in amino acid levels in mouse brain regions after adjunctive treatment of brexpiprazole with fluoxetine: comparison with (R)-ketamine. Psychopharmacology (Berl). 2017;234:3165–3173.
   PubMed Web of Science ®Google Scholar
• Ma M, Ren Q, Yang C, et al. Antidepressant effects of combination of brexpiprazole and fluoxetine on depression-like behavior and dendritic changes in mice after inflammation. Psychopharmacology (Berl). 2017;234:525–533.
   PubMed Web of Science ®Google Scholar
• Han C, Wang S-M, Kato M, et al. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. Expert Rev Neurother. 2013;13:851–870.
   PubMed Web of Science ®Google Scholar
• Šagud M, Mihaljević-Peleš A, Begić D, et al. Antipsychotics as antidepressants: what is the mechanism? Psychiatr Danub. 2011;23:302–307.
   PubMed Web of Science ®Google Scholar
• Al Shirawi MI, Edgar NE, Kennedy SH. Brexpiprazole in the treatment of major depressive disorder. Clin Med Insights Ther. 2017;9:1179559X17731801.
   Google Scholar
• Otsuka Pharmaceutical Co., Ltd. REXULTI TM product monograph 2017. [cited 2019 Mar 30]. Available from: https://pdf.hres.ca/dpd_pm/00038152.PDF.
   Google Scholar
• Rexulti (brexpiprazole) FDA approval history - drugs.com. Drugs.com n.d. Cited 2019 Mar 30]. Available from: https://www.drugs.com/history/rexulti.html
   Google Scholar
• Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015;76:1224–1231.
   PubMed Web of Science ®Google Scholar
• Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015;76:1232–1240.
   PubMed Web of Science ®Google Scholar
• Thase ME, Weiller E, Zhang P, et al. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies. Neuropsychiatr Dis Treat. 2019;15:37–45.
   PubMed Web of Science ®Google Scholar
• Parikh NB, Robinson DM, Clayton AH. Clinical role of brexpiprazole in depression and schizophrenia. Ther Clin Risk Manag. 2017;13:299–306.
   PubMed Web of Science ®Google Scholar
• Citrome L. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be hel. Int J Clin Pract. 2015;69:978–997.
   PubMed Web of Science ®Google Scholar
• Hobart M, Skuban A, Zhang P, et al. A randomized, placebo-controlled study of the efficacy and safety of fixed-dose brexpiprazole 2 mg/d as adjunctive treatment of adults with major depressive disorder. J Clin Psychiatry. 2018;79. DOI:10.4088/JCP.17m12058.
   Google Scholar
• McKeage K. Adjunctive brexpiprazole: a review in major depressive disorder. CNS Drugs. 2016;30:91–99.
   PubMed Web of Science ®Google Scholar
• Weiss C, Skuban A, Hobart M, et al. Incidence, onset, duration and severity of akathisia with adjunctive brexpiprazole (opc-34712) in major depressive disorder: analysis of two pivotal studies. American Society of Clinical Psychopharmacology Annual Meeting, Miami, Florida; 2015.
   Google Scholar
• Nelson CJ, Zhang P, Skuban A, et al. Overview of short-term and long-term safety of brexpiprazole in patients with major depressive disorder and inadequate response to antidepressant treatment. Curr Psychiatry Rev. 2016;12:278–290.
   Web of Science ®Google Scholar
• Cha DS, McIntyre RS. Treatment-emergent adverse events associated with atypical antipsychotics. Expert Opin Pharmacother. 2012;13:1587–1598.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectr. 2016;21:1–6.
   PubMed Web of Science ®Google Scholar
• Fava M, Okame T, Matsushima Y, et al. Switching from inadequate adjunctive or combination treatment options to brexpiprazole adjunctive to antidepressant: an open-label study on the effects on depressive symptoms and cognitive and physical functioning. Int J Neuropsychopharmacol. 2017;20:22–30.
   PubMed Web of Science ®Google Scholar
• Bauer M, Hefting N, Lindsten A, et al. A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder. Acta Neuropsychiatr. 2019;31:27–35.
   PubMed Web of Science ®Google Scholar
• Archives CP, Consult C, Skills CTTY, et al. Aripiprazole, brexpiprazole, and cariprazine: Not all the same. Curr Psychiatry. 2018;17:24–33.
   Google Scholar
• Ballenger JC. Anxiety and depression: optimizing treatments. Prim Care Companion J Clin Psychiatry. 2000;2:71.
   PubMedGoogle Scholar
• Gorman JM. Comorbid depression and anxiety spectrum disorders. Depress Anxiety. 1996;4:160–168.
   PubMedGoogle Scholar
• Davis LL, Ota A, Perry P, et al. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study. Brain Behav. 2016;6:e00520.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Weiller E, Zhang P, et al. Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials. J Affect Disord. 2016;201:116–123.
   PubMed Web of Science ®Google Scholar
• Fava M, Weiller E, Zhang P, et al. Efficacy of brexpiprazole as adjunctive treatment in major depressive disorder with irritability. J Clin Psychopharmacol. 2017;37:276–278.
   PubMed Web of Science ®Google Scholar
• Fava M, Ménard F, Davidsen CK, et al. Adjunctive brexpiprazole in patients with major depressive disorder and irritability. J Clin Psychiatry. 2016;77:1695–1701.
   PubMed Web of Science ®Google Scholar
• Krystal AD, Mittoux A, Meisels P, et al. Effects of adjunctive brexpiprazole on sleep disturbances in patients with major depressive disorder: an open-label, flexible-dose, exploratory study. Prim Care Companion CNS Disord. 2016;18. DOI:10.4088/PCC.15m01914
   Google Scholar
• Thase ME, Buysse DJ, Frank E, et al. Which depressed patients will respond to interpersonal psychotherapy? The role of abnormal EEG sleep profiles. Am J Psychiatry. 1997;154:502–509.
   PubMed Web of Science ®Google Scholar
• Coryell W, Young EA. Clinical predictors of suicide in primary major depressive disorder. J Clin Psychiatry. 2005;66:412–417.
   PubMed Web of Science ®Google Scholar
• Bernert RA, Joiner TE Jr, Cukrowicz KC, et al. Suicidality and sleep disturbances. Sleep. 2005;28:1135–1141.
   PubMed Web of Science ®Google Scholar
• McCall WV, Blocker JN, D’Agostino R Jr, et al. Insomnia severity is an indicator of suicidal ideation during a depression clinical trial. Sleep Med. 2010;11:822–827.
   PubMed Web of Science ®Google Scholar
• Gulec M, Selvi Y, Boysan M, et al. Ongoing or re-emerging subjective insomnia symptoms after full/partial remission or recovery of major depressive disorder mainly with the selective serotonin reuptake inhibitors and risk of relapse or recurrence: a 52-week follow-up study. J Affect Disord. 2011;134:257–265.
   PubMed Web of Science ®Google Scholar
• Amital D, Fostick L, Silberman A, et al. Serious life events among resistant and non-resistant MDD patients. J Affect Disord. 2008;110:260–264.
   PubMed Web of Science ®Google Scholar
• Lepine BA, Moreno RA, Campos RN, et al. Treatment-resistant depression increases health costs and resource utilization. Braz J Psychiatry. 2012;34:379–388.
   PubMed Web of Science ®Google Scholar
• North CS, Brown ES, Pollio DE. Expanded conceptualization of multimorbidity to encompass substance use disorders and other psychiatric illness. Ann Clin Psychiatry. 2016;28:182–188.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Lee Y, Mansur RB. Treating to target in major depressive disorder: response to remission to functional recovery. CNS Spectr. 2015;20(Suppl 1): 20–30. quiz 31.
   PubMedGoogle Scholar